BrainChip Holdings Ltd (ASX:BRN) Share Price Update – Akida 1500 Production Progress and Edge AI Development

Anjali Anand

05 August 2026 09:50 PM AEST

BrainChip Holdings Ltd (ASX:BRN) Share Price Update – Akida 1500 Production Progress and Edge AI Development

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

BrainChip Holdings Ltd (ASX:BRN) shares traded at $0.135, up $0.005 or 3.846% during the latest session.
The company recorded trading volume of 4,285,784 shares, with a market capitalisation of $295.85 million.
BrainChip received its first production batch of 2,000 AKD1500 neuromorphic processors during the June 2026 quarter.
The company ended the quarter with US$20.3 million in cash and cash equivalents.
BrainChip continued development of Akida-based platforms, licensing agreements and edge AI applications.

BrainChip Holdings Ltd (ASX:BRN) develops neuromorphic artificial intelligence technology focused on ultra-low-power edge AI processing. The company’s Akida™ technology is designed to enable AI processing closer to sensors, targeting applications across defence, industrial, infrastructure, autonomous systems, robotics and other edge computing markets.

The company’s quarterly activities report for the quarter ended 30 June 2026 highlighted progress in AKD1500 production, intellectual property licensing, ecosystem expansion, product development and commercialisation initiatives.

Share Price Performance and Trading Activity

BrainChip Holdings Ltd (ASX:BRN) shares traded at $0.135 during the latest session, increasing by $0.005 or 3.846%. The stock recorded a daily trading range between $0.130 and $0.140, compared with the previous close of $0.130.

Trading volume was 4,285,784 shares, compared with an average volume of 5,408,630 shares. BrainChip has a market capitalisation of $295.85 million, with 2,275,825,144 shares on issue.

The stock’s 52-week trading range was between $0.112 and $0.270.

AKD1500 Production Moves Towards Commercial Deployment

A key development during the June 2026 quarter was BrainChip’s receipt of the first production batch of AKD1500 neuromorphic processors. The initial production run included 2,000 units and represented the company’s transition from pre-production evaluation devices towards commercial-scale manufacturing.

BrainChip stated that the production units provide a foundation for customer deployments across defence, industrial, infrastructure and edge AI applications. Additional units are expected to be delivered during the third quarter, with the full production run expected to reach approximately 60,000 units, although this was lower than initially expected due to production yield outcomes.

Licensing and Partner Ecosystem Expansion

During the quarter, BrainChip delivered register-transfer level (RTL) design assets to EDGEAI under the previously announced Akida 2.0 licensing agreement.

The delivery enables EDGEAI to integrate BrainChip’s neuromorphic technology into future custom silicon solutions targeting smart metering and infrastructure applications. BrainChip stated that the milestone supports its intellectual property licensing model and potential future royalty opportunities.

The company also expanded its ecosystem through additional partnerships, including a strategic ecosystem partnership with MicroIP to deliver integrated hardware and software solutions for edge AI applications.

Hardware Platforms Support Customer Adoption

BrainChip plans to allocate more than 2,000 AKD1500 devices during the second half of calendar 2026 to develop multiple hardware platforms.

These platforms include M.2 accelerator modules, PCIe accelerator cards, Raspberry Pi 4 and Raspberry Pi 5 development boards, along with application-focused reference platforms including AkidaTag®, Akida Radar and Akida EW.

The company stated that these platforms are intended to support customer evaluation, software development, algorithm validation and system testing across industrial, communications, defence, infrastructure and edge AI applications.

Generative AI and Product Roadmap Development

BrainChip continued development of its Generative AI (GenAI) program during the quarter, with technical milestones achieved in model development and software infrastructure.

The company expects internal demonstrations of the GenAI platform during the latter part of the third quarter of calendar year 2026. BrainChip is also developing four AI models targeting radar and electronic warfare applications, including signal classification, threat detection, object identification and spectrum awareness.

The AKD2500 project also continued during the quarter, with the company remaining on schedule for an early December tapeout.

Cash Position and Quarterly Financial Update

BrainChip ended the June 2026 quarter with US$20.3 million in cash and cash equivalents, compared with US$25.3 million in the previous quarter.

Net operating cash outflows were US$4.7 million during the quarter, compared with US$5.3 million in the prior quarter. Customer receipts totalled US$149,000, while payments for research and development, product manufacturing, marketing, staff costs and corporate expenses contributed to operating cash outflows.

The company reported available funding of US$20.97 million, including US$20.305 million in cash and US$665,000 in unused financing facilities, representing an estimated 4.43 quarters of funding availability based on current operating cash flows.

LDA Put Option Agreement Expiration

BrainChip’s Put Option Agreement with LDA Capital expired on 30 June 2026. The company satisfied the outstanding contractual Failure Fee of A$1.0 million through liquidation of collateral shares held by LDA.

Approximately 6.96 million BrainChip shares were sold by LDA, generating gross proceeds of approximately A$1.0 million, which were applied towards the Failure Fee. The company stated that remaining collateral shares held by LDA were expected to be liquidated in an orderly manner.

Looking Ahead

BrainChip enters the second half of calendar 2026 focused on expanding commercialisation activities through AKD1500 production availability, customer deployments, licensing agreements and ecosystem development. The company is progressing hardware enablement platforms, GenAI initiatives and application-focused reference platforms while targeting long-term revenue opportunities through silicon sales, intellectual property licensing and royalties.

Conclusion

BrainChip Holdings Ltd (ASX:BRN) continues to progress its neuromorphic AI commercialisation strategy, with the June 2026 quarter marked by AKD1500 production delivery, licensing milestones, ecosystem expansion and continued product development.

The company’s latest update provides visibility into its transition towards commercial deployments, supported by ongoing technology development and customer engagement initiatives across edge AI markets.

FAQs

Q: What is the ASX code for BrainChip Holdings Ltd?

A:BrainChip Holdings Ltd trades on the Australian Securities Exchange under the code ASX:BRN.

Q: What was BrainChip’s latest share price?

A:BrainChip shares traded at $0.135 during the latest session, up $0.005 or 3.846%.

Q: What is the AKD1500 processor?

A:AKD1500 is BrainChip’s neuromorphic processor designed for ultra-low-power edge AI applications.

Q: How much cash did BrainChip hold at the end of June 2026?

A:BrainChip reported US$20.3 million in cash and cash equivalents at the end of the June 2026 quarter.

Q: What markets is BrainChip targeting?

A:BrainChip is targeting edge AI applications across areas including defence, industrial, infrastructure, autonomous systems, robotics and other technology markets.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.